What is the management approach for a patient with Chronic Kidney Disease stage 3 (CKD3)?

Case Study: Management of a Patient with CKD Stage 3

Patient Presentation

Mr. Johnson, a 62-year-old male with CKD Stage 3b (eGFR 38 mL/min/1.73m²), presents for routine follow-up.

Clinical Details:

• Past Medical History: Type 2 diabetes (12 years), hypertension (15 years), hyperlipidemia
• Current Medications: Metformin 1000mg BID, Lisinopril 20mg daily, Amlodipine 5mg daily, Atorvastatin 20mg daily
• Vital Signs: BP 148/92 mmHg, BMI 31 kg/m²
• Laboratory Results:
  • eGFR: 38 mL/min/1.73m² (down from 42 six months ago)
  • Serum creatinine: 1.8 mg/dL
  • Urine albumin-to-creatinine ratio (ACR): 450 mg/g
  • HbA1c: 7.8%
  • Potassium: 4.6 mEq/L
  • Bicarbonate: 20 mEq/L
  • Hemoglobin: 11.2 g/dL

---

Question 1: What is the most critical first-line pharmacological intervention to add to this patient's regimen?

Answer:

Initiate an SGLT2 inhibitor immediately, as this is now first-line therapy for CKD patients regardless of diabetes status and will provide the greatest benefit in slowing disease progression and reducing cardiovascular events. 1

The 2022 ADA/KDIGO consensus guidelines establish SGLT2 inhibitors as foundational therapy for CKD management, positioned even before optimizing other interventions. 1 This patient's eGFR of 38 mL/min/1.73m² is well above the threshold of 20 mL/min/1.73m² for initiation, and the medication should be continued until dialysis or transplantation. 1

Key implementation points:

• Start with empagliflozin 10mg daily or dapagliflozin 10mg daily 2
• Do not discontinue when eGFR falls below 20 mL/min/1.73m²—continue until dialysis 1
• Monitor for genital mycotic infections and volume depletion initially 2
• The cardiorenal benefits occur independent of glucose-lowering effects 3, 2

Why this takes priority over other interventions: The evidence demonstrates that SGLT2 inhibitors reduce CKD progression by approximately 30-40% and cardiovascular events by 20-30% in patients with diabetes and albuminuria. 3, 2 This represents the single most impactful intervention available for this patient's long-term outcomes. 1

---

Question 2: How should this patient's blood pressure management be optimized?

Answer:

Target blood pressure should be ≤130/80 mmHg given the significant albuminuria (450 mg/g), and the lisinopril dose must be titrated to the maximum tolerated dose before adding additional agents. 1, 4

The current BP of 148/92 mmHg is inadequate for a patient with albuminuria ≥30 mg/g. 4 The more intensive target of ≤130/80 mmHg (rather than ≤140/90 mmHg for non-albuminuric patients) provides maximum protection against both CKD progression and cardiovascular events. 1, 4, 5

Specific titration algorithm:

1. Maximize RAS inhibitor first: Increase lisinopril from 20mg to 40mg daily (maximum tolerated dose) 1

   • Monitor serum creatinine and potassium in 2-4 weeks 1
   • Accept creatinine increases up to 30% if no volume depletion 4
   • Do not discontinue for potassium <5.5 mEq/L 1

2. Add dihydropyridine calcium channel blocker: Increase amlodipine from 5mg to 10mg daily 1, 4

3. Add diuretic if still not at goal: Chlorthalidone 12.5-25mg daily or furosemide if eGFR <30 1

4. Consider nonsteroidal MRA: If albuminuria persists despite above measures and potassium remains normal, add finerenone 10-20mg daily 1

Critical pitfall to avoid: Do not combine ACE inhibitors with ARBs—this is harmful and increases adverse events without additional benefit. 1

---

Question 3: What monitoring frequency and parameters are required for this patient?

Answer:

Monitor eGFR, electrolytes, and therapeutic medication levels every 3-5 months, with more frequent monitoring (2-4 weeks) after any medication changes affecting the renin-angiotensin system. 4

For CKD Stage 3b with albuminuria and diabetes, this patient falls into the high-risk category requiring quarterly monitoring at minimum. 1, 4

Specific monitoring protocol:

Every 3-5 months (routine): 4

• Serum creatinine and eGFR
• Electrolytes (sodium, potassium, bicarbonate)
• Urine albumin-to-creatinine ratio
• HbA1c
• Lipid panel
• Complete blood count (hemoglobin)
• Calcium, phosphorus, PTH (for CKD-MBD screening)

2-4 weeks after medication changes: 1, 4

• Serum creatinine and potassium after RAS inhibitor titration
• Serum creatinine after SGLT2 inhibitor initiation

Additional assessments: 6, 4

• Blood pressure at every visit (home BP monitoring recommended)
• Medication adherence and review at each visit
• Assessment for volume status and orthostatic hypotension

Red flags requiring immediate evaluation: 4

• Serum creatinine increase >30% from baseline
• Potassium >5.5 mEq/L
• Bicarbonate <22 mEq/L (worsening acidosis)
• Hemoglobin <10 g/dL
• Rapid eGFR decline (>5 mL/min/1.73m² per year)

---

Question 4: What dietary and lifestyle modifications should be prescribed?

Answer:

Prescribe dietary protein restriction to exactly 0.8 g/kg body weight per day (approximately 70g daily for this patient), sodium restriction to <2,300 mg/day, and structured physical activity of 150 minutes weekly of moderate-intensity exercise. 1, 6, 4

These are not optional recommendations—they are evidence-based interventions that slow CKD progression. 6, 7, 3

Specific dietary prescription:

Protein intake: 1, 6, 4

• Calculate: 0.8 g/kg × 87 kg (assuming height ~175cm, BMI 31) = 70g protein daily
• Avoid high protein intake (>1.3 g/kg/day) which accelerates decline 6
• Emphasize plant-based proteins over animal proteins 7, 4

Sodium restriction: 1, 6, 4

• Strict limit of <2,300 mg (1 teaspoon) daily
• Avoid processed foods, canned soups, deli meats
• Use potassium-free salt substitutes cautiously given CKD

Dietary pattern: 7, 4

• Mediterranean-style, plant-based diet preferred
• Increase fruits, vegetables, whole grains, legumes
• Limit red meat, processed meats

Physical activity: 6, 7

• Minimum 150 minutes weekly of moderate-intensity activity (brisk walking, cycling)
• Break into 30-minute sessions, 5 days per week
• Resistance training 2 days per week

Weight management: 6, 7

• Target BMI <25 kg/m² (current BMI 31)
• Weight loss of 5-10% provides significant cardiorenal benefits
• Refer to registered dietitian for medical nutrition therapy

Smoking cessation: 1, 6

• Mandatory if patient smokes—tobacco accelerates CKD progression
• Offer pharmacotherapy (varenicline, bupropion, nicotine replacement)

---

Question 5: What additional pharmacological interventions are indicated?

Answer:

Increase statin intensity to high-dose (atorvastatin 40-80mg daily), add a GLP-1 receptor agonist for glycemic control and additional cardiorenal protection, and initiate oral alkali supplementation for metabolic acidosis. 1, 6

This patient requires comprehensive pharmacotherapy addressing multiple pathways of disease progression. 1

Cardiovascular risk reduction:

Statin therapy: 1, 4

• Increase atorvastatin from 20mg to 40-80mg daily
• All CKD patients ≥50 years require moderate-to-high intensity statins
• Target is not LDL level but maximal absolute LDL reduction
• Consider adding ezetimibe 10mg if LDL remains >70 mg/dL 1

Glycemic management:

GLP-1 receptor agonist: 1

• Add semaglutide 0.25mg weekly (titrate to 1mg) or dulaglutide 1.5mg weekly
• Provides additional albuminuria reduction beyond SGLT2 inhibitors
• Offers cardiovascular benefits and weight loss
• Safe with eGFR >15 mL/min/1.73m²

Metformin adjustment: 1, 4

• Continue current dose (eGFR 38 is above the 30 mL/min/1.73m² threshold)
• Discontinue if eGFR falls below 30 mL/min/1.73m²

Metabolic acidosis correction:

Oral alkali therapy: 6, 7

• Bicarbonate 20 mEq/L requires treatment (normal ≥22 mEq/L)
• Sodium bicarbonate 650mg (7.7 mEq) TID, or
• Sodium citrate/citric acid solution 15-30 mL TID
• Target serum bicarbonate 22-26 mEq/L
• Slows CKD progression and reduces muscle wasting

Anemia management:

Iron supplementation: 6, 7

• Hemoglobin 11.2 g/dL warrants evaluation
• Check iron studies (ferritin, transferrin saturation)
• Initiate oral iron (ferrous sulfate 325mg daily) if iron deficient
• Consider IV iron if oral iron ineffective or not tolerated
• Reserve erythropoiesis-stimulating agents for hemoglobin <10 g/dL

---

Question 6: When should this patient be referred to nephrology?

Answer:

Refer to nephrology immediately—this patient meets multiple criteria including eGFR <45 mL/min/1.73m², significant albuminuria (>300 mg/g), and progressive decline in kidney function. 7, 4

Delaying nephrology referral for advanced CKD (eGFR <30 mL/min/1.73m²) leads to poor outcomes, but this patient already warrants referral at stage 3b. 6, 4

Absolute indications for nephrology referral: 7, 4

• eGFR <30 mL/min/1.73m² (this patient is approaching this threshold)
• eGFR decline >5 mL/min/1.73m² per year (4 mL/min over 6 months suggests rapid progression)
• Albuminuria >300 mg/g (this patient has 450 mg/g)
• Uncertain etiology of CKD
• Difficult-to-control hypertension despite 3+ agents
• Persistent electrolyte abnormalities (metabolic acidosis present)
• CKD with diabetes requiring complex management

Timing considerations: 7, 4

• Urgent referral (within 2 weeks): Rapidly declining eGFR, severe complications
• Routine referral (within 3 months): eGFR 30-45 with albuminuria, as in this case
• Co-management model: Primary care continues routine management with nephrology guidance

Preparation for renal replacement therapy: 6, 7, 4

• Use Kidney Failure Risk Equation to estimate 2- and 5-year risk of kidney failure
• Begin education about dialysis and transplantation options
• Evaluate for living donor kidney transplantation (preferred option)
• Plan for vascular access (AV fistula) when eGFR approaches 20 mL/min/1.73m²
• Avoid subclavian vein catheterization to preserve future access sites

---

Question 7: What medications should be avoided or adjusted?

Answer:

Discontinue all NSAIDs immediately, avoid proton pump inhibitors unless absolutely necessary, adjust all renally-cleared medications for eGFR, and use extreme caution with iodinated contrast and gadolinium-based agents. 6, 4, 3

Nephrotoxin avoidance is critical to prevent acute-on-chronic kidney injury. 6, 4, 3

Absolute contraindications: 6, 4, 3

• NSAIDs (ibuprofen, naproxen, ketorolac)—use acetaminophen for pain instead
• COX-2 inhibitors (celecoxib)—equally nephrotoxic
• Combination ACE inhibitor + ARB therapy 1
• Aminoglycosides unless life-threatening infection with no alternatives

Medications requiring dose adjustment: 4

• Metformin: Reduce dose if eGFR 30-45, discontinue if <30 1
• Gabapentin: Reduce to 300mg daily (normally 900-3600mg)
• Enoxaparin: Reduce dose by 50% for eGFR <30
• Digoxin: Reduce dose and monitor levels closely
• Many antibiotics (fluoroquinolones, cephalosporins, penicillins)

Use with extreme caution: 4, 3

• Proton pump inhibitors: Associated with acute interstitial nephritis and CKD progression
• Lithium: Requires close monitoring and dose adjustment
• Calcineurin inhibitors (tacrolimus, cyclosporine): Nephrotoxic

Contrast considerations: 4

• Iodinated contrast: Use lowest possible dose, ensure adequate hydration
• Gadolinium-based contrast: Use only Group II or III agents (avoid Group I)
• Risk of nephrogenic systemic fibrosis with gadolinium at eGFR <30

Herbal and over-the-counter products: 4

• Review and limit use of dietary/herbal remedies
• Many contain nephrotoxic compounds or interact with medications
• Avoid high-dose vitamin C (oxalate nephropathy risk)

---

Summary of Immediate Action Plan

Within 1 week:

• Start SGLT2 inhibitor (empagliflozin 10mg or dapagliflozin 10mg daily) 1
• Increase lisinopril to 40mg daily 1
• Increase amlodipine to 10mg daily 1
• Increase atorvastatin to 40-80mg daily 1
• Start sodium bicarbonate 650mg TID 6, 7
• Discontinue any NSAIDs 6, 4, 3
• Refer to nephrology 7, 4
• Refer to registered dietitian for medical nutrition therapy 6, 4

Within 2-4 weeks:

• Recheck creatinine, eGFR, and potassium after RAS inhibitor titration 1, 4
• Add GLP-1 receptor agonist if glycemic control inadequate 1
• Check iron studies and initiate supplementation if indicated 6, 7

Within 3 months:

• Nephrology consultation completed 7, 4
• Reassess all parameters (eGFR, albuminuria, BP, HbA1c, lipids) 1, 4
• Consider adding nonsteroidal MRA if albuminuria persists 1